Thrombolytic Administration for Acute Ischemic Stroke
Background: The therapeutic benefit of tissue plasminogen activator (tPA) for acute ischemic stroke is provenbut extremely time-dependent. Current guidelines recommend a <60 minute door-to-needle time. We identify here factors affecting door-to-needle time of tPA administration for acute ischemi...
Main Authors: | Abraham Akbar, Nicholas Peoples, Hangyu Xie, Paulina Sergot, Haitham Hussein, William Frank Peacock IV, Zubaid Rafique |
---|---|
Format: | Article |
Language: | English |
Published: |
McGill University
2022-03-01
|
Series: | McGill Journal of Medicine |
Subjects: | |
Online Access: | https://mjm.mcgill.ca/article/view/881 |
Similar Items
-
Thrombolytic therapy for ischemic stroke
by: Natalia Vyacheslavovna Pizova
Published: (2013-11-01) -
Intravenous thrombolytic therapy in acute ischemic stroke: The art and science of treatment decision making
by: Sylaja P, et al.
Published: (2008-01-01) -
Difficult questions of intravenous thrombolytic therapy in ischemic stroke
by: Aleksey A. Kulesh
Published: (2021-11-01) -
EVALUATION OF EARLY ISCHEMIC CHANGES IN STROKE PATIENTS TREATED WITH THROMBOLYTIC THERAPY
by: Kolevski Goran, et al.
Published: (2016-07-01) -
Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report
by: Toshiyuki Ohtani, et al.
Published: (2019-12-01)